Next Article in Journal
Occurrence of Fusarium spp. and Fumonisins in Stored Wheat Grains Marketed in Iran
Next Article in Special Issue
Spider-Venom Peptides as Therapeutics
Previous Article in Journal
Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease
Previous Article in Special Issue
Novel Cytotoxic Vectors Based on Adeno-Associated Virus
Open AccessReview

Targeted Secretion Inhibitors—Innovative Protein Therapeutics

Syntaxin Ltd, Units 4-10 The Quadrant, Barton Lane, Abingdon, OXON, OX14 3YS, UK
*
Author to whom correspondence should be addressed.
Toxins 2010, 2(12), 2795-2815; https://doi.org/10.3390/toxins2122795
Received: 15 October 2010 / Revised: 16 November 2010 / Accepted: 2 December 2010 / Published: 3 December 2010
(This article belongs to the Special Issue Toxins as Therapeutics)
Botulinum neurotoxins are highly effective therapeutic products. Their therapeutic success results from highly specific and potent inhibition of neurotransmitter release with a duration of action measured in months. These same properties, however, make the botulinum neurotoxins the most potent acute lethal toxins known. Their toxicity and restricted target cell activity severely limits their clinical utility. Understanding the structure-function relationship of the neurotoxins has enabled the development of recombinant proteins selectively incorporating specific aspects of their pharmacology. The resulting proteins are not neurotoxins, but a new class of biopharmaceuticals, Targeted Secretion Inhibitors (TSI), suitable for the treatment of a wide range of diseases where secretion plays a major role. TSI proteins inhibit secretion for a prolonged period following a single application, making them particularly suited to the treatment of chronic diseases. A TSI for the treatment of chronic pain is in clinical development. View Full-Text
Keywords: botulinum neurotoxins; biologics; protein therapeutics; recombinant proteins; genetic engineering; SNARE proteins botulinum neurotoxins; biologics; protein therapeutics; recombinant proteins; genetic engineering; SNARE proteins
Show Figures

Graphical abstract

MDPI and ACS Style

Keith, F.; John, C. Targeted Secretion Inhibitors—Innovative Protein Therapeutics. Toxins 2010, 2, 2795-2815.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop